Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
15.43
+0.28 (1.85%)
At close: Jan 7, 2026, 4:00 PM EST
15.48
+0.05 (0.32%)
After-hours: Jan 7, 2026, 6:30 PM EST
Wave Life Sciences Employees
As of December 31, 2024, Wave Life Sciences had 288 total employees, including 287 full-time and 1 part-time employees. The number of employees increased by 20 or 7.46% compared to the previous year.
Employees
288
Change (1Y)
20
Growth (1Y)
7.46%
Revenue / Employee
$379,271
Profits / Employee
-$423,424
Market Cap
2.82B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 288 | 20 | 7.46% |
| Dec 31, 2023 | 268 | 16 | 6.35% |
| Dec 31, 2022 | 252 | 14 | 5.88% |
| Dec 31, 2021 | 238 | 18 | 8.18% |
| Dec 31, 2020 | 220 | -81 | -26.91% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
WVE News
- 2 days ago - Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 23 days ago - Why Did Wave Life Sciences Surge 147%? - Forbes
- 4 weeks ago - Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - What's Going On With Wave Life Sciences Stock Tuesday? - Benzinga
- 4 weeks ago - Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript - Seeking Alpha
- 4 weeks ago - Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss - GlobeNewsWire
- 4 weeks ago - Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 - GlobeNewsWire